Top Page
HUTCHMED (China) Limited
(LSE:0013)
HUTCHMED (China) Limited (0013) vs. S&P 500 (SPY)
HUTCHMED (China) Limited Business Overview & Revenue Model
HUTCHMED (China) Limited Financial Statement Overview
| Breakdown | ||||
| Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 838.00M | 426.41M | 356.13M | 227.98M | 204.89M | Gross Profit |
| 151.55M | 115.31M | 97.89M | 39.46M | 44.74M | EBIT |
| 18.38M | -409.77M | -336.46M | -188.95M | -145.02M | EBITDA |
| 67.27M | -401.11M | -329.27M | -182.89M | -135.13M | Net Income Common Stockholders |
| 100.78M | -410.14M | -227.66M | -194.56M | -144.38M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 886.34M | 631.00M | 1.01B | 435.18M | 217.17M | Total Assets |
| 1.28B | 1.03B | 1.37B | 724.12M | 465.12M | Total Debt |
| 86.13M | 23.30M | 34.07M | 35.71M | 33.08M | Net Debt |
| -197.46M | -289.98M | -343.48M | -199.92M | -88.07M | Total Liabilities |
| 536.39M | 392.57M | 333.15M | 205.17M | 152.22M | Stockholders Equity |
| 730.54M | 610.37M | 986.89M | 484.12M | 288.01M |
| Cash Flow | Free Cash Flow | |||
| 186.65M | -305.26M | -220.98M | -81.65M | -89.48M | Operating Cash Flow |
| 219.26M | -268.60M | -204.22M | -62.07M | -80.91M | Investing Cash Flow |
| -291.14M | 296.59M | -306.32M | -125.44M | 119.03M | Financing Cash Flow |
| 48.66M | -82.76M | 650.03M | 296.43M | -1.49M |
HUTCHMED (China) Limited Technical Analysis
HUTCHMED (China) Limited Peers Comparison
HUTCHMED (China) Limited Corporate Events
HUTCHMED announced that it will present new and updated data from several studies at the AACR Annual Meeting 2025, highlighting the progress of its compounds, including savolitinib, fruquintinib, and surufatinib. These presentations underscore HUTCHMED’s ongoing efforts to advance cancer treatment options and strengthen its position in the oncology field, potentially impacting its market presence and offering new hope for patients with various types of cancer.
HUTCHMED has completed patient enrollment for a Phase II registration study of savolitinib in gastric cancer patients with MET amplification in China. The study aims to evaluate the efficacy, safety, and tolerability of savolitinib, with interim results showing promising response rates. The drug has received Breakthrough Therapy Designation from China’s National Medical Products Administration, and if successful, HUTCHMED plans to seek marketing authorization in China by late 2025. This development could enhance HUTCHMED’s position in the oncology market, potentially offering a new treatment option for patients with MET-driven gastric cancer, which currently has a poor prognosis.
HUTCHMED (China) Limited announced the intended retirement of two Independent Non-executive Directors, Mr. Paul Rutherford Carter and Mr. Graeme Allan Jack, who have served for over eight years. Their retirement will lead to changes in the composition of the board committees, with new appointments including Professor Mok Shu Kam, Tony as Senior and Lead Independent Non-executive Director, Mr. Wong Tak Wai as chairman of the Audit Committee, Dr. Chaohong Hu as a member of the Audit Committee, and Dr. Renu Bhatia as chairman of the Remuneration Committee. These changes are expected to impact the company’s governance and strategic direction, ensuring continued integrity and transparency in financial reporting and remuneration practices.
HUTCHMED announced promising results from its SAVANNAH Phase II trial, showcasing high response rates for savolitinib combined with TAGRISSO® in MET-high lung cancer, offering a potential chemo-free treatment strategy. The company also reported long-term survival benefits from its Phase IIIb study of savolitinib in MET exon 14 NSCLC, and explored surufatinib as a maintenance therapy in small cell lung cancer, indicating strong potential for these treatments in improving patient outcomes.
HUTCHMED (China) Limited has filed its annual report on Form 20-F with the U.S. Securities and Exchange Commission for the fiscal year ending December 31, 2024. This filing is a regulatory requirement and provides stakeholders with comprehensive information about the company’s financial performance and management’s assessment of internal controls. The filing indicates that HUTCHMED is a well-known seasoned issuer and continues to meet its reporting obligations, reflecting its stable position in the market.
HUTCHMED reported a 65% growth in oncology product revenue for 2024, achieving profitability and financial self-reliance ahead of schedule. Significant milestones included the commercialization of FRUZAQLA® outside China, positive clinical trial results for several drugs, and the development of a new ATTC platform. The company also agreed to a partial disposal of its equity in SHPL for $608 million, which will support further development of its drug pipeline. These developments position HUTCHMED for continued global growth and expansion of its innovative drug portfolio.
HUTCHMED and Innovent Biologics have announced that their FRUSICA-2 Phase II/III study has met its primary endpoint for the combination treatment of fruquintinib and sintilimab in advanced renal cell carcinoma (RCC) in China. This development marks a significant advancement in RCC treatment, offering a promising new option for patients who have not responded adequately to previous therapies. The study’s positive results highlight the potential of this combination therapy to address unmet medical needs in the RCC patient population, reinforcing HUTCHMED’s commitment to advancing cancer treatments.
HUTCHMED (China) Limited has announced the disposal of a 45% equity interest in Shanghai Hutchison Pharmaceuticals Limited (SHPL). The transaction involves selling 35% of SHPL to GP Health Service Capital and 10% to Shanghai Pharma. This strategic move is structured through various agreements, including the GP Health SPA and Shanghai Pharma SPA, with designated purchasers acquiring specific equity interests. The sale is valued at approximately RMB2.5 billion for a portion of the shares, reflecting a calculated valuation based on SHPL’s net profit. This disposal is expected to impact HUTCHMED’s financial structure and market positioning, potentially providing liquidity and focusing resources on core operations.